Wecome Pharmaceutical Co Ltd (300878) — Cash Flow-to-Debt Ratio
Wecome Pharmaceutical Co Ltd (300878) has a Cash Flow-to-Debt Ratio of 0.00x as of September 2025, meaning its operating cash flow of CN¥-1.42 Million could theoretically repay 0% of its total liabilities (CN¥458.37 Million) in one year. See 300878 cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Wecome Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio (2013–2024)
Historical debt coverage capacity for Wecome Pharmaceutical Co Ltd across 12 annual periods. Also explore Wecome Pharmaceutical Co Ltd (300878) net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Wecome Pharmaceutical Co Ltd (2013–2024)
Year-by-year debt coverage analysis for Wecome Pharmaceutical Co Ltd. For market capitalisation and broader financial context, see market value of Wecome Pharmaceutical Co Ltd.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.06x | CN¥-27.17 Million | CN¥478.50 Million | ▼ -162.3% |
| 2023 | 0.09x | CN¥58.29 Million | CN¥639.23 Million | ▼ -68.8% |
| 2022 | 0.29x | CN¥146.57 Million | CN¥502.25 Million | ▲ +222.5% |
| 2021 | -0.24x | CN¥-67.74 Million | CN¥284.28 Million | ▼ -236.0% |
| 2020 | 0.18x | CN¥42.81 Million | CN¥244.39 Million | ▼ -44.7% |
| 2019 | 0.32x | CN¥112.76 Million | CN¥356.02 Million | ▼ -25.8% |
| 2018 | 0.43x | CN¥105.57 Million | CN¥247.29 Million | ▲ +155.6% |
| 2017 | 0.17x | CN¥29.00 Million | CN¥173.68 Million | ▼ -82.6% |
| 2016 | 0.96x | CN¥100.15 Million | CN¥104.25 Million | ▲ +197.8% |
| 2015 | 0.32x | CN¥29.63 Million | CN¥91.84 Million | ▼ -33.5% |
| 2014 | 0.49x | CN¥46.01 Million | CN¥94.82 Million | ▲ +35.9% |
| 2013 | 0.36x | CN¥25.98 Million | CN¥72.78 Million | — |